Trospium Chloride Micronized Powder
NDC Package 46016-1041-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Trospium Chloride Micronized powders is a medication used to treat an overactive bladder. This formulation utilizes a powder delivery system. Marketed by Procos S.p.a., this product is identified by NDC 46016-1041.

Identification & Billing

NDC Package Code
46016-1041-0
Package Description
50 kg in 1 CONTAINER
Product Code
46016-1041
11-Digit Billing Format
46016104100

Clinical Specifications

Proprietary Name
Trospium Chloride Micronized
Non-Proprietary Name
Trospium Chloride Micronized
Substance Name
Trospium Chloride
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
TROSPIUM CHLORIDE 50 kg/50kg
Usage Information
This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Regulatory & Marketing

Labeler Name
Procos S.p.a.
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
12-28-2010
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 46016-1041-0 identifies a specific commercial package of 50 kg in 1 container of Trospium Chloride Micronized (UNFINISHED drug), a bulk ingredient labeled by Procos S.p.a.. This powder is formulated for use and contains trospium chloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Procos S.p.a. on December 28, 2010. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

How is this Procos S.p.a. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 46016104100. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
46016-1041-0
11-Digit CMS (5-4-2)
46016-1041-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.